FDA Guidance Will Spur More Companion Diagnostic/Drug Trials – Nuvelo Exec
This article was originally published in The Gray Sheet
Executive Summary
Unclear regulatory pathways for molecular diagnostic tests used to predict patients' response to particular drug therapies can impede the FDA approval process, Abbott Diagnostics Regulatory Affairs Director Matthew Klamrzynski maintained
You may also be interested in...
FDA Pharmacogenetic Regulation: Three Guidances, Fall Workshop
FDA is planning to issue three guidances on pharmaco-genomics over the next 18 months
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.